Drug Discovery Services Market to Reach USD 61.3 Bn by 2032

Key Highlights

• The Drug Discovery Services Market was valued at USD 21.39 Bn in 2025.
• The market is expected to reach USD 61.3 Bn by 2032.
• Revenue is projected to grow at a CAGR of 16.23% during 2026–2032.
• CDER approved 50 new drugs in 2025.
• Around 5,100 pharmaceutical companies have active R&D departments for drug discovery.
• Medicinal chemistry services held the largest type-segment share in 2025.
• Respiratory systems accounted for approximately 16.8% of global revenue in 2025.
• North America was the largest regional market in 2025.
• Asia Pacific is expected to post the highest CAGR during the forecast period.

Why This Matters Now

Pharma and biotech companies are under pressure to cut discovery cost without slowing pipelines. CROs now sit closer to the center of drug innovation because outsourcing is becoming a capital-efficiency strategy.

Drug Discovery Services Market rise from USD 21.39 Bn in 2025 to USD 61.3 Bn by 2032 signals a structural shift in how new medicines are discovered. Large pharma is reducing internal discovery dependence, while biologics, rare disease programs and AI-led discovery workflows expand demand for specialized external partners.

Market Overview

Drug discovery is the process of identifying potential new medicines across biology, chemistry and pharmacology. The market includes target selection, target validation, hit-to-lead identification, lead optimization and candidate validation. It also covers medicinal chemistry, biology services and drug metabolism and pharmacokinetics.

MMR states that major pharmaceutical companies are collaborating with clinical research organizations to boost profitability and reduce R&D expenditure. This changes the CRO role from vendor to strategic research partner. Sponsors gain access to infrastructure, talent and integrated platforms without carrying the full fixed cost.

The market is also expanding because drug pipelines are becoming more complex. Biologics, biosimilars and large-molecule drugs require specialized testing at each stage. That makes outsourcing more attractive for pharma companies trying to manage cost, risk and scientific complexity.

Download PDF Brochure: https://www.maximizemarketresearch.com/request-sample/6672/

Key Trends Driving Growth

AI is becoming a major discovery tool. MMR states that AI can analyze drug research results and protein structures before a chemical is synthesized. This can help predict target impact and safety issues earlier in development.

Biologics are reshaping service demand. MMR states that more than half of drug candidates in the discovery stage are biologics, including proteins, peptides and monoclonal antibodies. Biologics need specialized services, which increases CRO demand.

Chronic disease burden is increasing pipeline pressure. MMR identifies cancer, diabetes, cardiovascular disease and respiratory disease as major drivers. Chronic diseases account for seven out of every 10 deaths worldwide, representing more than 40 million deaths per year.

R&D investment is expanding outsourcing demand. Biopharma companies are spending more on research activities, orphan drugs and rare disease programs. Sponsors are using CROs to increase productivity and reduce financial burden.

Regulation is also shaping the market. MMR notes that safety, efficacy and animal-research rules increase development cost. This creates demand for better models, including biosimulation, but skilled labor shortages and high target-molecule failure rates remain barriers.

Segment Insights

• Dominant Type Segment: Medicinal Chemistry Services. Medicinal chemistry services held the largest market share in 2025. Growth is driven by chemistry’s role in early drug development and the need to deliver robust candidates.
• Important Service Areas: Biology Services and DMPK. MMR lists biology services and drug metabolism and pharmacokinetics as major type segments. These services support preclinical decision-making and candidate quality.
• Process Segments: Target Selection, Target Validation, Hit-to-Lead Identification, Lead Optimization and Candidate Validation. The visible summary lists these process segments but does not identify a dominant process segment.
• Therapeutic Area Insight: Respiratory Systems. Respiratory systems accounted for approximately 16.8% of global revenue in 2025, supported by bronchitis, TB, COPD, asthma and drug resistance.
• Therapeutic Area Insight: Oncology. MMR identifies oncology as dominant in therapeutic categories and expected to remain important because cancer-drug demand is rising globally.
• End-User Segments: Pharmaceutical & Biotechnology Companies, Academic Institutes and Other End Users. Other end users include small CROs, IVD companies and clinical laboratories.
• Fastest-Growing Segment: Not disclosed in the visible MMR summary. The page identifies Asia Pacific as the highest-CAGR region but does not label a fastest-growing service or end-user segment.

Regional Growth Story

North America was the largest regional market for drug discovery services in 2025. MMR links this to established CROs, rising R&D expenditure by pharmaceutical and biopharmaceutical companies, growth in biosimilars and biologics, and access to advanced instruments and facilities. The United States is included in the regional scope, but separate market revenue is not disclosed.

Europe is included in the report scope, with the UK and Germany listed among covered countries. MMR provides one UK disease-burden signal: lung illnesses account for about 700,000 hospital admissions and more than 6 million inpatient bed days each year. This supports respiratory discovery demand, but the visible summary does not provide UK or Germany revenue.

Asia Pacific is expected to have the highest CAGR during the forecast period. MMR states the region is emerging as a hub for outsourced drug discovery because of skilled labor, lower cost, a good regulatory framework and high-quality data. China, India, South Korea and Japan are included in the scope.

Japan is specifically identified as the world’s second-largest pharmaceutical sector and a significant opportunity for CROs. The revised Pharmaceutical Affairs Law in Japan supports research in tissue diagnostics and cancer. That creates a favorable setting for outsourced discovery and translational research.

Competitive Landscape

The market is led by CROs, discovery specialists, analytical testing companies and platform-enabled service providers. MMR lists Charles River Laboratories, WuXi AppTec, Eurofins Discovery, Evotec, IQVIA, Syngene International, Thermo Fisher Scientific, Labcorp, GenScript Biotech, Pharmaron Beijing, Jubilant Biosys, Sygnature Discovery, Aragen Life Sciences, Piramal Pharma Solutions, Lonza Group, Frontage Laboratories, Selvita, Domainex, Concept Life Sciences, BioDuro, Viva Biotech, Aurigene Discovery Technologies, Schrödinger, Curia and MedChemExpress.

Competition is shifting toward integrated service models. Sponsors want speed, lower cost and scientific depth across early discovery, analytics and clinical translation. CROs with AI, medicinal chemistry, biology, DMPK and global trial handoff capabilities are better positioned than narrow service providers.

Download PDF Brochure: https://www.maximizemarketresearch.com/request-sample/6672/

Recent Developments

• Lonza restructured operations into three integrated platforms, including Advanced Synthesis, to support commercial scale-up by mid-2025. The move aims to streamline CDMO workflows and link discovery to production more efficiently.
• Eli Lilly was forecast to overtake competitors in the metabolic space by 2026, driven by high R&D investment in incretin therapies. This increases demand for specialized outsourcing in metabolic disease drug discovery.
• Nucleus Network completed the acquisition of Hammersmith Medicines Research to create an early-phase provider network across Australia, the U.S. and the UK. The merger gives sponsors more jurisdictional flexibility for first-in-human trials.
• Novartis announced an agreement to acquire Avidity Biosciences for approximately USD 12 Bn. The move signals stronger demand for RNA-based discovery services and neuromuscular disease pipelines.
• GSK committed USD 30 Bn to U.S.-based R&D over five years. This is expected to increase demand for outsourced discovery and clinical activity.
• IQVIA launched a strategic collaboration with Flagship Pioneering to give portfolio companies access to AI-powered clinical research services.

Strategic Implications

For pharma companies, outsourcing is now a strategic lever. It helps control fixed costs, fill capability gaps and accelerate discovery across complex biologics and rare disease programs.

For CROs, the opportunity is moving upstream. Sponsors want integrated support from target validation to lead optimization and early clinical readiness.

For investors, AI-enabled service models are gaining relevance. Partnerships such as Bayer and Exscientia show how computational discovery can improve speed and candidate selection.

For regulators and health systems, higher drug approvals increase the need for stronger discovery validation. The market will reward services that reduce failure risk and improve evidence quality.

Future Outlook

The Drug Discovery Services Market is set to grow as pharma outsourcing, biologics, rare disease research, AI-enabled discovery and chronic disease demand reshape R&D. North America leads today, while Asia Pacific offers the highest-CAGR opportunity through cost, talent and outsourcing infrastructure.

Future leaders will be CROs that combine AI, medicinal chemistry, biologics expertise and global execution before discovery outsourcing becomes a scale-and-data contest.

Related Reports

Patient Registry Software Market: https://www.maximizemarketresearch.com/market-report/global-patient-registry-software-market/3695/

Global Immuno-oncology Drugs Market: https://www.maximizemarketresearch.com/market-report/global-immuno-oncology-drugs-market/98268/

Prescription Pharmaceuticals Market: https://www.maximizemarketresearch.com/market-report/prescription-pharmaceuticals-market/330/

Analyst Perspective

“According to Komal Patil, Research Manager at Maximize Market Research, ‘The Drug Discovery Services Market is projected to grow from USD 21.39 Bn in 2025 to USD 61.3 Bn by 2032 at a 16.23% CAGR, driven by pharma R&D outsourcing, AI-enabled discovery, biologics and chronic disease pipelines. Medicinal chemistry services lead because early candidate quality remains central to development success. Companies that integrate scientific depth, AI workflows and global CRO execution will be better positioned as drug discovery becomes faster, more outsourced and more competitive.’”

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting company that provides reliable, data-focused, and practical business insights. The firm serves a wide range of industries, including healthcare, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. Through market forecasts, competitive analysis, strategic consulting, and industry impact assessments, MMR helps organizations understand changing market conditions, identify growth opportunities, and make informed business decisions for long-term success.

2nd Floor, Navale IT Park Phase 3

Pune Banglore Highway, Narhe

Pune, Maharashtra 411041, India

+91 9607365656

sales@maximizemarketresearch.com